Marketed drugs cleared by aldehyde oxidase (AO) are few, with no known clinically relevant pharmacokinetic drug interactions associated with AO inhibition, while cytochrome P450 inhibition or induction mediates a number of clinical drug interactions. Little attention has been given to consequences of co-administering a P450 inhibitor with a compound metabolized by both AO and P450. Upon discovering that VU0409106 (1) was metabolized by AO (to M1) and P450 enzymes (to M4-M6), we sought to evaluate the in vivo disposition of 1 and its metabolites in rats with attenuated P450 activity. Male rats were orally pretreated with the pan-P450
Introduction
The 2012 US Food and Drug Administration (FDA) draft guidance on defining the drug interaction potential of new chemical entities (NCEs) in drug discovery and development (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/u cm292362.pdf) focuses primarily on human in vitro and nonclinical in vivo approaches to model clinical drug-drug interactions (DDIs) involving cytochrome P450s and drug efflux proteins (Prueksaritanont et al., 2006; Di et al., 2013; Prueksaritanont et al., 2013) . However, sparse attention has been paid to the potential for drug interactions involving compounds metabolized by enzymes falling outside these two classes of drug disposition proteins. One such enzyme receiving recent attention is the molybdenum-containing flavoprotein, aldehyde oxidase (AO). In particular, significant strides have been made towards understanding the structure-activityrelationships of AO binding and metabolism (Beedham et al., 1995; Dalvie et al., 2012; Coelho et al., 2015) , species differences (Beedham et al., 1987; Garattini and Terao, 2012; Dalvie et al., 2013) , human AO variability (Hartmann et al., 2012; Hutzler et al., 2014) , and inhibition of AO in vitro (Obach et al., 2004; Barr and Jones, 2011) , while studies defining the importance of this enzyme in an in vivo drug interaction scenario are lacking, perhaps owing to a deficiency of well-established specific AO inhibitors considered suitable for in vivo pharmacokinetic studies.
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3A4, the secondary route of zaleplon metabolism (http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020859s011lbl.pdf). Additionally, changes in exposure to the chemotherapeutic idealisib were noted with co-administration of the P450 3A inhibitor ketoconazole, or the inducer rifampin (Ramanathan et al., 2016) . A noteworthy report recently indicated an important role for AO in a drug interaction between BILR 355 and the P450 3A inhibitor ritonavir, where co-administration resulted in a metabolic "switch" from P450 3A metabolism of BILR 355 to gut bacterial and subsequent AO metabolism (Li et al., 2012a; Li et al., 2012b) . Furthermore, Li's studies monitoring formation of this AO metabolite in human S9 in the presence and absence of NADPH were consistent with a metabolic shunt towards AO when the P450 pathway was inactive. This report brought attention to the possibility of a drug interaction leading to a metabolic switch and the potential for AO to contribute to such an event.
We previously reported the disposition of a novel mGlu 5-negative allosteric modulator, VU0409106 (1), which was discovered to be predominantly metabolized by AO (Scheme 1), to the primary metabolite, M1 (Morrison et al., 2012) . Notably, we demonstrated that the in vitro scaled hepatic clearance (CL HEP ) of 1 was in general agreement with the in vivo plasma clearance (CL p ) observed in Sprague-Dawley (SD) rats and cynomolgus monkey. Our continued interest in 1 has been driven largely by the observation that P450 pathways also contribute to its biotransformation, resulting in formation of metabolites M4, M5 and M6. While Li's report demonstrates a drug interaction that elicits a metabolic switch in a unique scenario requiring an intermediate gut bacterial metabolism step, we hypothesized that hepatic P450 inhibition may result in an elevated exposure to the AO metabolite of a drug cleared via both AO and P450
enzymes. Because AO and P450 commonly generate different metabolites due to opposing This article has not been copyedited and formatted. The final version may differ from this version. Sprague-Dawley (SD) rat hepatic microsomes and S9 were obtained from BD Biosciences (San Diego, CA). All solvents or reagents were of the highest purity commercially available.
Biotransformation of 1 in multispecies hepatic microsomes and S9 fractions.
Hepatic micromsomal metabolism of 1. The in vitro metabolism of 1 was investigated in rat and human hepatic microsomal fractions. A potassium phosphate-buffered reaction (100 mM, pH 7.4) of 1 (10 μM), hepatic microsomes (1 mg/mL), MgCl 2 (3 mM) and NADPH (2 mM) was incubated at 37°C in borosilicate glass test tubes under ambient oxygenation for 60 minutes. The total incubation volume was 0.5 mL. Reactions were initiated by the addition of 1, terminated with the addition of 2 volumes of acetonitrile, and subsequently centrifuged at 3500 rcf for 10 min. The resulting supernatant was dried under a stream of nitrogen and reconstituted in 85:15 (v/v) ammonium formate (10 mM, pH 4.1):acetonitrile in preparation for LC/MS analysis.
M1 formation in multispecies hepatic S9 fractions.
Similarly the metabolism of 1 and subsequent formation of M1 in rat and human hepatic S9 fractions (2.5 mg/mL; +/-1 mM NADPH) was investigated. Total incubation volume was 200 μL. Reactions were initiated with addition of 1 (1 μM), and at designated times (t = 0, 7, 15, 30, 45 , and 60 min), aliquots were removed and precipitated with ice-cold acetonitrile containing an internal standard This article has not been copyedited and formatted. The final version may differ from this version. Intrinsic clearance in multispecies hepatic S9 fractions. To explore potential kinetic mechanisms responsible for our observations of M1 formation in S9, we measured the intrinsic clearance (CL int ) of 1 in rat and human S9 fractions at three different concentrations of 1, using NADPH and hydralazine to isolated the NADPH-dependent (P450), NADPH-independent (AO), and total (P450 + AO) hepatic S9 CL int for each species. For measurement of total, NADPHindependent, and NADPH-dependent S9 CL int , compound 1 (0.1 μM, 1 μM, or 10 μM) was incubated as described above in rat or human S9 fractions in the presence or absence of NADPH, or in the presence of NADPH after pre-incubation with the AO-specific inhibitor hydralazine (50 μM), respectively. Rat and human S9 CL int (mL/min/kg) was estimated using the substrate depletion method and Eq. 1: 0.1 min followed by a re-equilibration (0.4 min) with a total run time of 2.7 min, or alternatively started at 30% B after a 0.2 min hold and was linearly increased to 90% B over 0.8 min; held at 90% B for 0.5 min and returned to 30% B in 0.1 min followed by a re-equilibration (0.9 min) with a total run time of 2.5 min. HPLC flow rate was 0.5 mL/min. The source temperature was set at 500°C, and mass spectral analyses were performed using multiple reaction monitoring, with transitions and voltages specific for 1 or its metabolites using a Turbo Ion Spray source in positive ionization mode (5.0 kV spray voltage). Data were analyzed using Sciex Analyst 1.5.1
software. Concentrations of 1 were determined using a matrix-matched 9-point standard curve
(lower limit of quantitation = 0.5 ng/mL). As no authentic standard was available to determine metabolite concentrations, a semi-quantitative analysis was expressed as the analyte peak:internal standard ratio (internal standard, carbamazepine) (Morrison et al., 2012) . 
Metabolite detection. LC/UV/MS analysis of metabolites generated in vitro

Data analysis.
This article has not been copyedited and formatted. The final version may differ from this version. incubations, absent the P450 reducing cofactor NADPH, was greater than that observed when incubations were fortified with NADPH ( Figure 1 ). An approximate 50% increase in the area under the curve (AUC) of M1 was observed in S9 incubations absent NADPH relative to those incubations containing NADPH from both human and rat experiments (Table 2 ). We previously demonstrated that subsequent metabolism of M1 to M2 is catalyzed by xanthine oxidase (XO; Scheme 1) (Morrison et al., 2012) , an enzyme which does not require the reducing cofactor NADPH for catalytic activity, thus excluding P450-mediated conversion of M1 to M2 as the mechanism responsible for this observation. The observed increase in M1 in S9 incubations absent NADPH may likely be due to an increase in substrate exposure to AO in the absence of NADPH-dependent P450 metabolism. To explore this possibility, we measured the CL int of 1 in rat and human S9 fractions in the presence and absence of NADPH and in the presence of NADPH and the AO inhibitor, hydralazine, to estimate the CL int mediated by both AO and P450, AO only, and P450 only, respectively (Table 3) , and over a concentration range of 1 (0.1 μM, 1
This article has not been copyedited and formatted. The final version may differ from this version. Altogether, the present in vitro data indicate that SD rat represents an acceptable nonclinical model to study the in vivo disposition of 1 and its metabolites under drug interaction duress (e.g., P450 inhibition), particularly the occurrence of metabolic shunting from P450 towards AO.
ABT pretreatment results in increased exposure to parent 1 and the AO metabolite M1 in vivo in SD rats.
To evaluate the impact of P450 inhibition on the disposition of 1 and its metabolites, SD rats received an IP administration of 1 (3 mg/kg) with or without oral ABT (50 mg/kg) pretreatment.
We then generated standard plasma time-concentration profiles ( Figure 2) pretreatment. In rats pretreated with ABT, a 7.8-fold increase in the plasma AUC of 1 was observed ( Figure 2A , Table 4 ). Likewise, the C max was increased 3.1-fold. The PK of 1 was also obtained (Table 4) , following a parenteral administration of 1 to rats, where an increase in AUC of 1 was again observed (3.5-fold), along with a corresponding reduction in the average CL p from 53.5 to 15.3 mL/min/kg in rats pretreated with ABT.
We also observed an increase in the exposure to the AO metabolite M1 in rats receiving the ABT pretreatment, with a 15-fold and 7.3-fold increases in the average AUC and C max values, respectively ( Figure 2B , Table 5 ). We submit that this finding is consistent with the contributions of a shunting mechanism towards the AO pathway when P450 activity is attenuated by ABT (as was observed in hepatic S9 incubations of 1 that were absent NADPH). We previously reported that M1 is converted to M2 via XO, followed by an oxidative-defluorination to M3 (Scheme 1) (Morrison et al., 2012) . Consequently, a substantial increase in M2 was also observed in rats as a result of ABT pretreatment (11-fold and 14-fold increase in mean C max and AUC, respectively) ( Figure 2D , Table 5 ). While the increase in M2 can be explained by an increase in its precursor metabolite, M1, we considered the possibility that accumulation of M2 in ABT-pretreated rats occurred as a result of reduced P450-mediated conversion of M2→M3, with the potential to reduce the rate of M1 conversion to M2 (e.g., product inhibition). In order to investigate contributions of secondary P450-mediated metabolism of M2 to the observed plasma levels of M1, rats were orally administered either ABT (50 mg/kg), the XO inhibitor allopurinol (50 mg/kg), or a combination of the two inhibitors prior to the IP injection of compound 1 (10 mg/kg). Similar to rats receiving the 3 mg/kg dose of 1, rats receiving the 10 mg/kg dose displayed a 14-fold increase in the AUC of M2 when pretreated with ABT ( Figure 3A , Table 6 ).
M2 was below the detection limits in rats pretreated with the XO inhibitor allopurinol and was
This article has not been copyedited and formatted. The final version may differ from this version. detectable only at the latter time points collected from rats pretreated with both allopurinol and ABT (data not shown). Pretreatment with allopurinol revealed a relatively small increase of 2.6-fold in the AUC of M1 compared to a 9.1-fold increase following ABT pretreatment ( Figure 3B , Table 6 ). Importantly, when rats were pretreated with both allopurinol and ABT, the AUC of M1 increased 15-fold ( Figure 3B , Table 6 ; see Supplemental Figure 2 for ABT and allopurinol exposure). These data indicate that the accumulation of M1 from inhibition of the M2→M3 pathway is likely a minimal contributing factor towards the increase in M1 exposure in rats experiencing the ABT-induced DDI duress.
The P450-mediated metabolites M4 and M6 were monitored to ascertain the impact of ABT pretreatment in vivo ( Figure 2C ). Due to the complexity in the chromatographic resolution of M4
and M6, their isobaric mass, as well as their identical MS/MS transitions, LC/MS/MS peak areas of these metabolites were grouped accordingly, for the purpose of determining a semiquantitative plasma-time concentration profile and exposure analysis as a measure of the contribution of P450 in the metabolism of 1 in vivo. While a decrease was observed in the C max of M4-M6 (0.64-fold), a 2.1-fold increase was observed in the AUC of these metabolites in the ABT pretreated rats (Table 5 ). This observation may be due to alterations in the secondary metabolism and clearance mechanisms acting on M4 and/or M6.
This article has not been copyedited and formatted. The final version may differ from this version. towards the uninhibited pathway (e.g., AO) when another pathway is inhibited (e.g., P450). It is unlikely that the elevated M1 levels were due to a decrease in M1 clearance in rats pretreated with ABT, as the major M1 clearance pathway in vitro was previously determined to be XOmediated metabolism to M2 (Morrison et al., 2012) . And while the activation of AO has been previously suggested (Nirogi et al., 2014) , the present increased M1 formation observed in hepatic S9 fractions absent NADPH relative to NADPH-containing reactions indicate there to be no contribution from an ABT-mediated cooperativity on AO. Furthermore, data from our This article has not been copyedited and formatted. The final version may differ from this version. when ABT was present (data not shown). Finally, while the induction of AOX1 in mice, rats, and rabbits (Garattini and Terao, 2012) has been demonstrated, an induction mechanism accounting for our observations is highly unlikely, given the single dose study design and duration thereof.
Our observed increase in M1, therefore, appears to have primarily resulted from a condition of increased substrate availability to AO when the P450 pathway(s) of metabolism was attenuated.
In additional support of this mechanism, the decrease in NADPH-dependent S9 CL int (P450 pathway), with a maintenance of NADPH-independent S9 CL int (AO pathway) with increased concentrations of 1, indicates a lower K m, P450 relative to the K m, AO , according to the relationship:
where V max is the enzyme's maximum reaction velocity, K m is the substrate concentration that yields half the maximal velocity, and S is the substrate concentration. Incidentally, our findings associate an increase in metabolite exposure with the co-administration of 1 and an enzyme inhibitor, whereas this type of DDI situation would typically be anticipated with coadministration of a victim drug and an enzyme inducer or stimulator. We might have expected this metabolic shunting observation to prevent an extensive increase in the AUC of 1, with AO compensating for loss of P450 activity. However, as ABT is a pan-P450 inactivator, we have likely forced the shunt towards a single enzyme (AO), potentially limiting the capacity for compensation (versus inhibiting one enzyme with the possibility of shunting towards multiple enzymes).
While the M4-M6 AUC unexpectedly increased in ABT-pretreated rats, the significant increase in AUC and decrease in the total body CL of parent 1 indicates ABT did inhibit P450-metabolism of 1 in vivo. A possible explanation for this observation is that ABT also inhibited This article has not been copyedited and formatted. The final version may differ from this version. secondary metabolism of M4-M6. Alternatively, as M4 and M6 were quantified together, it is also possible that the AUC of one metabolite was increased, while that of the other was decreased, potentially resulting from differences in inhibitory activity towards enzymes responsible for formation and/or clearance of M4 and M6. Prior studies of ABT inhibitory activity towards human P450 enzymes found that P450 2C9 is only minimally impacted by ABT (60% remaining activity following 30 min pretreatment of human liver microsomes with 1 mM ABT) (Linder et al., 2009) ; the differential inhibitory activity of ABT towards rat P450 isoforms is unknown. Presently, we found there to be an approximate 65% decrease in M4 compared to a 25% increase in M6 in pooled plasma samples (1-6 hours) from rats pretreated with ABT relative to control rats (Supplemental Figure 3) , indicating ABT may have differentially impacted the disposition of the two metabolites.
Besides significant increases in exposure to parent compound 1, mean increases observed in the AUC and C max of the AO metabolite M1 highlight the potential for a drug interaction resulting from increased exposure to a metabolite of a drug with both AO and P450 clearance routes when co-administered with a P450 inhibitor. Clinically used drugs exhibiting a major clearance pathway via AO are few, and to date, no clinically relevant DDIs resulting from AO inhibition have been recognized, despite the identification of many clinical drugs demonstrating AO inhibition in vitro (Obach et al., 2004) . However, our data indicate that inhibition of alternate clearance routes (e.g., P450) for drugs also metabolized by AO may result in elevation of a circulating AO-mediated metabolite, which importantly, could have clinical implications when metabolites exhibit pharmacogical or toxicological activity (Smith and Obach, 2005) . For example, cases of dose-dependent renal toxicity associated with AO-mediated formation of a low-solubility metabolite have been reported for methotrexate (Smeland et al., 1996) , 2013; Lolkema et al., 2015) . Additionally, the primary circulating metabolite of idealisib, GS-563117, is a mechanism-based inhibitor of P450 3A, which is not the case for the parent drug. In this instance, however, both AO and P450 3A (minor) contribute to the formation of GS-563117 (Ramanathan et al., 2016) .
While a small percentage of currently marketed drugs are cleared via AO, a recent study indicated the proportion of NCEs in research and development containing potentially AOsusceptible moieties is much higher (Pryde et al., 2010) . Drug discovery scientists are more frequently encountering AO metabolism due to incorporation of nitrogen-containing aromatic rings for either target engagement (e.g. kinases) or mitigation of P450 metabolism (reduced lipophilicity). As many AO substrates (e.g., zaleplon and idealisib) are known to also undergo metabolism via enzymes other than AO (Strelevitz et al., 2012; Ramanathan et al., 2016) , it is likely that current and future NCEs exhibiting AO metabolism will also undergo metabolism via alternate enzymes. As such, metabolic shunting may be important to consider during toxicology and DDI assessment of these compounds. Likewise, this consideration may also be important for
NCEs not displaying AO metabolism without concomitant administration of an enzyme
inhibitor, yet containing an AO-susceptible structural moiety (potential for metabolic switching (Li et al., 2012a; Li et al., 2012b) ). The likelihood of substantial elevations in metabolite exposure (via metabolic shunting) may be increased for drugs cleared by both AO and P450 enzymes versus drugs cleared only by multiple P450 pathways, as different P450 enzymes commonly generate the same metabolite, in which case the metabolite would be expected to be generated at decreased or similar levels when one of the P450 pathways is inhibited.
This article has not been copyedited and formatted. The final version may differ from this version. In conclusion, our studies with 1 and ABT using rat as a nonclinical PK model revealed increased exposure to both the parent drug and the AO metabolite. The present investigation highlights the potential drug interactions that may occur with co-administration of a P450
inhibitor and a mixed AO/P450 substrate. The similarities we observed in vitro between SD rat and human in the formation of AO and P450 metabolites, trends in the impact of P450 activity on the formation of M1, and in the kinetic behavior of the two enzymatic pathways indicate that our observations in vivo in rat may translate to human in vivo. We submit that rat may offer a nonclinical model to probe drug interactions (and mechanisms thereof) where a mixed AO:P450
substrate experiences a clinical drug interaction duress, while underscoring the potential existence of the compound-dependent use of nonclinical models to predict AO-mediated interactions. As investigators are more frequently encountering AO metabolism through the drug discovery and development continuum, understanding the drug interaction potential for drugs exhibiting an AO clearance component will be important in the successful advancement and safe clinical implementation of future drug candidates bearing this nonP450 phenotype.
This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. AUC 0-inf (h*ng/mL) 311 ± 6.52 1099 ± 85.7 * 3.5 3 mg/kg (IP) C max (ng/mL) 787 ± 782 2453 ± 589 * 3.1 AUC 0-inf (h*ng/mL) 482 ± 247 3742 ± 970 ** 7.8 AUC = area under the plasma concentration-time curve; C max = peak plasma concentration; CL = plasma clearance; t 1/2 = half-life (t 1/2 = MRT* ln2); Vss = volume of distribution at steady-state. Data for control and ABT groups represent a mean of n = 2 (± SEM). Data for control (n = 3) and ABT (n = 4) groups represent a mean (± SD). Statistical analysis performed using a two-tailed unpaired t test. *p <0.05, **p < 0.01
This article has not been copyedited and formatted. The final version may differ from this version. 1.20 ± 1.10 17.1 ± 11.9 14 n/a n/a n/a n/a AUC reported as peak area ratio analyte/IS*h, as no authentic metabolite standards were available. Data represent a mean of n = 2 (± SEM). Statistical analyses performed using a two-tailed unpaired t test. *p <0.05, **p < 0.01
